FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Takeda | Japan | Vaccine | Novartis

Novartis inks pact to enter Japanese vax market


Novartis has struck a deal with Takeda that will allow the Swiss pharma giant entry into the world's third largest vaccine market.

Takeda has agreed to pay Novartis a little more than a million dollars upfront along with milestones and royalties for Vaxem-Hib, a vaccine for the Haemophilus influenza Type B (Hib). Takeda takes on responsibility for clinical trials in Japan and will file the NDA for the vaccine, which will be sold under the Novartis name.

Japan's vaccine market is valued at $640 million and is widely expected to grow more.

- read the report from Reuters

Related Articles:
Novartis pays $20M up front for vax program
Xoma, Novartis restructure vaccine agreement
Novartis plans trials for growing vaccines pipeline
Novartis eyes vaccines with Protez purchase

More stories about Vaccine   Novartis   Takeda   Japan  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.